Praxis Precision Medicines, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Filed November 7, 2023. Praxis is a clinical-stage biopharmaceutical company developing CNS therapies through its Cerebrum small-molecule and Solidus antisense oligonucleotide platforms. It has no product sales.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $0.5 million | None | $1.9 million | None |
| Research and development | $17.3 million | $30.4 million | $68.4 million | $126.7 million |
| General and administrative | $8.7 million | $13.9 million | $32.1 million | $46.8 million |
| Net loss | $24.6 million | $43.9 million | $96.4 million | $172.9 million |
| Net loss per share, basic and diluted | $0.18 | $0.96 | $1.12 | $3.79 |
| Net cash used in operating activities | Not provided for the quarter | Not provided for the quarter | $87.3 million | $156.2 million |
At September 30, 2023, cash and cash equivalents were $101.1 million; the company held no marketable securities. Total assets were $106.7 million, total liabilities $20.0 million, and stockholders’ equity $86.8 million. No debt balance is reported in the balance sheet. Operating cash flow was negative; the filing does not present a gross margin measure. Other income was $0.9 million for Q3 and $2.2 million for the nine-month period.
Material changes and financing
- Net loss narrowed year over year, alongside lower operating expenses. Nine-month R&D declined $58.3 million, mainly reflecting reduced Cerebrum spending—including lower PRAX-114 costs following the 2022 strategic realignment—and lower personnel costs. Solidus R&D increased $2.4 million, partly due to the PRAX-222 EMBRAVE study.
- Nine-month G&A fell $14.7 million, primarily from lower professional fees, consulting, and personnel costs. These cost reductions should be considered against the company’s stated plans to maintain or increase investment as trials advance.
- Cash and cash equivalents increased from $61.6 million at December 31, 2022 to $101.1 million. Financing provided $87.7 million in the first nine months, including $63.4 million net from the June follow-on offering and $24.1 million net from at-the-market sales. The June offering included 64.45 million common shares and pre-funded warrants for 7.05 million shares.
- Common shares outstanding rose from 49.38 million at year-end 2022 to 128.55 million at September 30, 2023; the filing reports 128,550,152 shares outstanding as of November 3, 2023. Pre-funded warrants were unexercised at September 30, but their underlying shares are included in weighted-average shares for loss-per-share purposes.
Outlook, programs, and risks
- Management estimated that September 30 cash would fund operating and capital requirements into the first quarter of 2025, based on its current plan, which advances candidates through—but not beyond—their current clinical trials. The liquidity note separately says cash is expected to cover at least one year from issuance. Both estimates rely on assumptions; management warns funds could be used sooner and additional financing may be needed. The company expects operating losses and negative operating cash flows for the foreseeable future.
- Management reported initiating Phase 3 studies of ulixacaltamide (PRAX-944) for essential tremor in Q4 2023, with enrollment expected to finish in the first half of 2024 and topline results in the second half of 2024. PRAX-562 Phase 2 topline results were expected in the first half of 2024. PRAX-628 PPR study results were anticipated in Q4 2023, followed by a planned focal epilepsy Phase 2 study in the first half of 2024. Elsunersen (PRAX-222) first-cohort dosing was completed, with preliminary data announced in October 2023.
- Under its UCB collaboration, Praxis recognizes revenue as it performs research services. The agreement includes a $5.0 million upfront payment; UCB has an option to license resulting candidates. Praxis may receive an option fee, up to $98.5 million in development and commercialization milestones, and royalties if applicable; these potential payments are contingent and not guaranteed.
- Clinical-stage development entails substantial execution and funding risks, including trial enrollment, safety and efficacy outcomes, regulatory approval, manufacturing, intellectual-property protection, and competition. The company cautions that preliminary or topline clinical data can change after further review.
- Stockholders approved a reverse-split authorization on November 6, 2023, after quarter-end, allowing the board to select a ratio from 1-for-5 to 1-for-25. The filing warns the split may not sustain the share-price increase sought and could reduce liquidity or increase volatility.
- No material legal proceedings were reported. Management concluded disclosure controls were effective as of September 30, 2023.
Key facts for investors to verify
- Whether trial timelines and results for PRAX-944, PRAX-562, PRAX-628, and PRAX-222 meet the company’s stated expectations, and how final data compare with interim or preliminary disclosures.
- Whether the stated cash runway remains achievable as clinical-trial spending changes, and the timing, amount, and terms of any additional financing.
- The dilution implications of the June 2023 offering, outstanding pre-funded warrants, equity awards, and any further equity issuance.
- Progress and economics of the UCB collaboration, including whether UCB exercises its option and whether contingent milestones or royalties become payable.
- Whether the board effects the approved reverse split, at what ratio, and the resulting effects on trading liquidity and share price.